- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
VistaGen Therapeutics Outlines Steps After PALISADE-3 Completion
Company focuses on execution improvements for ongoing PALISADE-4 study of fasedienol in social anxiety disorder
Published on Feb. 13, 2026
Got story updates? Submit your updates here. ›
VistaGen Therapeutics (NASDAQ:VTGN) used its fiscal 2026 third-quarter corporate update call to outline steps it is taking after the completion of the randomized portion of PALISADE-3, a Phase 3 trial of fasedienol in social anxiety disorder (SAD). The company emphasized execution improvements for the ongoing PALISADE-4 study and provided updates on its women's health candidate PH80, now designated rafisolone.
Why it matters
VistaGen's efforts to optimize the PALISADE-4 study and analyze data across the PALISADE program could help the company better understand the drivers of both fasedienol and placebo response, potentially informing future regulatory discussions. The company's progress on rafisolone for women's health also represents an expansion of its pipeline.
The details
VistaGen said it has reviewed available PALISADE-3 data and implemented 'moderate refinements' to PALISADE-4, including retraining, site rationalization, and other operational enhancements to address a 'higher placebo response' observed in PALISADE-3 compared to PALISADE-2. The company is also working with third-party collaborators to apply 'innovative approaches' to analyze datasets across the PALISADE program, with the goal of better understanding the drivers of both fasedienol and placebo response. Management emphasized that any changes to the PALISADE-4 statistical analysis plan would require resubmission and alignment with the FDA.
- VistaGen expects to follow a similar communications pattern to PALISADE-3, referencing a public update after 'the last patient's last visit' and then moving toward top-line results.
- The company remains 'on track with guidance' previously given for PALISADE-4 top-line results for the randomized portion, but did not provide specific enrollment numbers.
The players
VistaGen Therapeutics
A clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders.
Shawn Singh
Chief Executive Officer of VistaGen Therapeutics.
PH80
VistaGen's women's health candidate, now designated rafisolone, a hormone-free, nonsystemic, intranasal product candidate for moderate to severe vasomotor symptoms (hot flashes) due to menopause.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
